RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma

BackgroundEwing's sarcomas are aggressive musculoskeletal tumors occurring most frequently in the long and flat bones as a solitary lesion mostly during the teen-age years of life. With current treatments, significant number of patients relapse and survival is poor for those with metastatic disease. As part of novel target discovery in Ewing's sarcoma, we applied RNAi mediated phenotypic profiling to identify kinase targets involved in growth and survival of Ewing's sarcoma cells.ResultsFour Ewing's sarcoma cell lines TC-32, TC-71, SK-ES-1 and RD-ES were tested in high throughput-RNAi screens using a siRNA library targeting 572 kinases. Knockdown of 25 siRNAs reduced the growth of all four Ewing's sarcoma cell lines in replicate screens. Of these, 16 siRNA were specific and reduced proliferation of Ewing's sarcoma cells as compared to normal fibroblasts. Secondary validation and preliminary mechanistic studies highlighted the kinases STK10 and TNK2 as having important roles in growth and survival of Ewing's sarcoma cells. Furthermore, knockdown of STK10 and TNK2 by siRNA showed increased apoptosis.ConclusionIn summary, RNAi-based phenotypic profiling proved to be a powerful gene target discovery strategy, leading to successful identification and validation of STK10 and TNK2 as two novel potential therapeutic targets for Ewing's sarcoma.

[1]  A. Lazar,et al.  Ewing’s Sarcoma: Standard and Experimental Treatment Options , 2009, Current treatment options in oncology.

[2]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[3]  D. Javelaud,et al.  NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B. , 2001, Oncogene.

[4]  J. Howlin,et al.  TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells , 2008, Breast Cancer Research.

[5]  W. Kaelin,et al.  Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen , 2008, Proceedings of the National Academy of Sciences.

[6]  K. Nishida,et al.  Tyrosine phosphorylation of ACK in response to temperature shift‐down, hyperosmotic shock, and epidermal growth factor stimulation , 1996, FEBS letters.

[7]  SaraAntonia Li,et al.  Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. , 2006, Pharmacology & therapeutics.

[8]  A. Llombart‐Bosch,et al.  Immunohistochemical Detection of EWS and FLI-1 Proteins in Ewing Sarcoma and Primitive Neuroectodermal Tumors: Comparative Analysis With CD99 (MIC-2) Expression , 2001, Applied immunohistochemistry & molecular morphology : AIMM.

[9]  P. Åman,et al.  Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib , 2008, Cancer Cell International.

[10]  P. Sorensen,et al.  EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Osuna,et al.  Advances in Ewing's sarcoma research: where are we now and what lies ahead? , 2009, Cancer research.

[12]  T. Triche,et al.  Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas , 2009, Molecular Cancer Therapeutics.

[13]  P. Lollini,et al.  CD99 engagement: an effective therapeutic strategy for Ewing tumors. , 2000, Cancer research.

[14]  H. Yonekawa,et al.  Molecular cloning of the human gene STK10 encoding lymphocyte-oriented kinase, and comparative chromosomal mapping of the human, mouse, and rat homologues , 1999, Immunogenetics.

[15]  Robert E. Brown,et al.  Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. , 2009, Annals of clinical and laboratory science.

[16]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[17]  Jeffrey P. MacKeigan,et al.  Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance , 2005, Nature Cell Biology.

[18]  E. Nishida,et al.  LOK Is a Novel Mouse STE20-like Protein Kinase That Is Expressed Predominantly in Lymphocytes* , 1997, The Journal of Biological Chemistry.

[19]  E. Nishida,et al.  Ste20‐like kinase (SLK), a regulatory kinase for polo‐like kinase (Plk) during the G2/M transition in somatic cells , 2000, Genes to cells : devoted to molecular & cellular mechanisms.

[20]  G. Martiny-Baron,et al.  Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. , 1993, The Journal of biological chemistry.

[21]  P. Anderson,et al.  Novel therapeutic approaches in pediatric and young adult sarcomas , 2006, Current oncology reports.

[22]  Wei Zheng,et al.  Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. , 2004, Assay and drug development technologies.

[23]  Meredith C Henderson,et al.  Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer , 2009, Journal of Translational Medicine.

[24]  F. van Valen,et al.  PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death , 2005, British Journal of Cancer.

[25]  Serge Batalov,et al.  Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. , 2003, Molecular cell.

[26]  M. Gishizky,et al.  Stk10, a New Member of the Polo-like Kinase Kinase Family Highly Expressed in Hematopoietic Tissue* , 2003, The Journal of Biological Chemistry.

[27]  P. Sabbatini,et al.  GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers , 2009, Molecular Cancer Therapeutics.

[28]  Fangzhou Song,et al.  Silencing of Polo-Like Kinase (Plk) 1 via siRNA Causes Inhibition of Growth and Induction of Apoptosis in Human Esophageal Cancer Cells , 2008, Oncology.

[29]  T. Kataoka,et al.  Epidermal growth factor stimulation of the ACK1/Dbl pathway in a Cdc42 and Grb2-dependent manner. , 2001, Biochemical and biophysical research communications.

[30]  John G Doench,et al.  Kinase requirements in human cells: I. Comparing kinase requirements across various cell types , 2008, Proceedings of the National Academy of Sciences.

[31]  Robert A Copeland,et al.  Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. , 2008, Cancer research.

[32]  L. Lim,et al.  Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas , 1999, Nature Cell Biology.

[33]  P. Meltzer,et al.  Gene expression profiling of human sarcomas: insights into sarcoma biology. , 2005, Cancer research.

[34]  X. Miao,et al.  Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. , 2009, World journal of gastroenterology.

[35]  Aideen Long,et al.  Statistical methods for analysis of high-throughput RNA interference screens , 2009, Nature Methods.

[36]  H. Koeffler,et al.  A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies , 2009, Leukemia.

[37]  M. Grace,et al.  Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells , 2008, Proceedings of the National Academy of Sciences.

[38]  Manuel Hidalgo,et al.  Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125 , 2008 .

[39]  J. Khoury.  Ewing Sarcoma Family of Tumors , 2005, Advances in anatomic pathology.

[40]  J. Dixon,et al.  Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. , 1998, Trends in biochemical sciences.

[41]  E. Álava,et al.  Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target , 2009, British Journal of Cancer.

[42]  Tesshi Yamada,et al.  Functional genome screen for therapeutic targets of osteosarcoma , 2009, Cancer science.

[43]  A. Üren,et al.  Pediatric malignancies provide unique cancer therapy targets , 2005, Current opinion in pediatrics.

[44]  D. Grueneberg,et al.  Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines , 2008, Proceedings of the National Academy of Sciences.

[45]  S. Loibl,et al.  Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells , 2002, Oncogene.

[46]  Y. Okano,et al.  EWS-Fli1 Up-Regulates Expression of the Aurora A and Aurora B Kinases , 2008, Molecular Cancer Research.

[47]  S. Donaldson,et al.  Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Lessnick,et al.  GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance , 2009, Oncogene.

[49]  W. May,et al.  GLI1 Is a Central Mediator of EWS/FLI1 Signaling in Ewing Tumors , 2009, PloS one.

[50]  J. Ludwig.  Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future , 2008, Current opinion in oncology.

[51]  J. Ban,et al.  EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin , 2005, Oncogene.

[52]  Masahiro Kurosaka,et al.  Inhibition of PKCalpha activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412. , 2008, Anticancer research.

[53]  Jun Yoshimatsu,et al.  Polo-like kinases (Plks) and cancer , 2005, Oncogene.